Arvinas
Arvinas' revenue fell 0.3% to $263 million in fiscal 2025. Its operating margin was −45.1%, up from −95.0% a year earlier. Free cash flow was −$276 million. It paid out $92 million in dividends and buybacks. The diluted share count fell 1.4%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Arvinas does
Arvinas is a clinical-stage biotechnology company, meaning its medicines are still being tested in people. It develops a type of drug called a PROTAC, which is designed to use the body's own protein disposal system to remove proteins that cause disease, rather than just block them.
Its most advanced candidate is vepdegestrant, for a form of advanced breast cancer. The FDA had accepted its New Drug Application, the request to approve a drug for sale, as of the filing. Its other candidates target proteins linked to Parkinson's disease and a related brain disease, to certain cancers including pancreatic, colorectal and lung, to a type of lymphoma, and to a muscle condition.
Arvinas has never had revenue from product sales. It works with other companies on early research, including Pfizer and Genentech. In April and September 2025 it cut its workforce under a cost savings plan.
Its biggest risks, as it describes them
- It has lost money since it started and may never be profitable.
- It will need substantial more funding, and may have to cut programs if it cannot raise it.
- Its PROTAC approach is unproven, so the time, cost and chance of success are hard to predict.
- It has no approved products, and may not be able to commercialize its candidates.
- Its 2025 workforce reductions may not save as much as expected and could disrupt its business.
Income statement
Arvinas lost money in fiscal 2025: a net loss of $81 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1,503 | 1,205 | 1,261 | 1,039 | 685 |
| Debt incl. finance leases | 1 | 1 | 1 | 1 | 1 |
| Net debt (negative means net cash) | −1,502 | −1,204 | −1,260 | −1,039 | −685 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.0x | 0.0x | 0.0x | 0.0x | 0.0x |
| Interest coverage | — | — | — | — | — |
| Current ratio | 5.9x | 4.2x | 5.0x | 4.6x | 4.9x |
| Quick ratio | 5.9x | 4.2x | 5.0x | 4.6x | 4.9x |
Cash flow
Projections
Project Arvinas' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
No officer, director or 10% owner of Arvinas reported buying or selling its shares on the open market between November 14, 2025 and November 13, 2026.
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 2 of 8 | 3 of 8 | 5 of 8 |
| Rule of 40 | −487.0% | 136.4% | −105.3% |
| Altman Z'' | 0.82 | 0.03 | −1.73 |
| Accruals ratio | −1.5% | 5.0% | 21.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Fail | Fail |
| Debt fell relative to assets | Fail | Pass | Pass |
| Current ratio rose | Pass | Fail | Pass |
| Share count didn't rise | Fail | Fail | Pass |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 2 of 8 | 3 of 8 | 5 of 8 |
Compare
Put Arvinas side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Arvinas | FY25 | −0.3% | −45.1% | −105.0% | — | — | 5 | |
| Iovance Biotherapeutics | FY25 | 60.6% | −153.1% | −127.6% | — | — | — | Compare |
| Ligand Pharmaceuticals | FY25 | 60.4% | 15.3% | 18.2% | 4.9% | −3.8x | 5 | Compare |
| Vericel | FY25 | 16.4% | 4.0% | 9.0% | — | — | — | Compare |
| Adaptive Biotechnologies | FY25 | 54.8% | −20.6% | −17.7% | −37.2% | — | 5 | Compare |
9 years of figures
| Fiscal year | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|
| Income statement | |||||||||
| Revenue | 8 | 14 | 43 | 26 | 54 | 131 | 78 | 263 | 263 |
| Revenue growth | — | 89.0% | 200.2% | −39.8% | 107.0% | 145.2% | −40.3% | 235.5% | −0.3% |
| Gross profit | — | — | — | — | — | — | — | — | — |
| Research and development | 29 | 45 | 67 | 108 | 180 | 315 | 380 | 348 | 285 |
| Operating income | −25 | −44 | −52 | −121 | −188 | −263 | −402 | −250 | −118 |
| Net income | −24 | −42 | −70 | −119 | −191 | −282 | −367 | −199 | −81 |
| Diluted EPS (US$) | −15.08 | −25.45 | −2.13 | −3.02 | −3.82 | −5.31 | −6.62 | −2.77 | −1.14 |
| Diluted shares (millions) | 2 | 9 | 33 | 40 | 50 | 53 | 56 | 72 | 71 |
| Cash flow | |||||||||
| Cash from operations | 5 | −16 | −41 | −90 | 559 | −274 | −348 | −259 | −274 |
| Capital expenditure | 1 | 3 | 6 | 6 | 5 | 7 | 3 | 2 | 2 |
| Free cash flow | 4 | −19 | −47 | −96 | 555 | −280 | −351 | −261 | −276 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 92 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 12 | 20 | 30 | 57 | 76 | 72 | 88 | 44 |
| Balance sheet at fiscal year end | |||||||||
| Cash and short-term investments | 39 | 188 | 281 | 689 | 1,503 | 1,205 | 1,261 | 1,039 | 685 |
| Debt incl. finance leases | 0 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 |
| Total assets | 67 | 199 | 302 | 717 | 1,582 | 1,269 | 1,305 | 1,091 | 718 |
| Total liabilities | 67 | 63 | 75 | 75 | 800 | 704 | 645 | 530 | 284 |
| Shareholders' equity | −61 | 137 | 227 | 642 | 782 | 565 | 660 | 562 | 434 |
| Margins and ratios | |||||||||
| Gross margin | — | — | — | — | — | — | — | — | — |
| Operating margin | −326.7% | −305.8% | −119.8% | −466.4% | −351.5% | −200.3% | −511.5% | −95.0% | −45.1% |
| Net margin | −317.3% | −289.6% | −163.5% | −460.6% | −356.3% | −215.0% | −467.9% | −75.5% | −30.8% |
| Free cash flow margin | 54.1% | −132.3% | −109.1% | −371.0% | 1,034.9% | −213.3% | −446.8% | −99.1% | −105.0% |
| Rule of 40 (growth + FCF margin) | — | −43.3% | 91.1% | −410.8% | 1,141.8% | −68.2% | −487.0% | 136.4% | −105.3% |
| Return on capital | — | — | — | — | — | — | — | — | — |
| Return on equity | — | −110.1% | −38.7% | −27.5% | −26.8% | −42.0% | −60.0% | −32.6% | −16.2% |
| Return on assets | — | −31.2% | −28.1% | −23.4% | −16.6% | −19.8% | −28.6% | −16.6% | −8.9% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — |